Menu
Recruiting NCT06707220

The Türkiye Heart Failure Registry

— Observational Heart Failure

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Heart failure medication.
Who it may be relevant to
Registry conditions: Heart Failure. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Turkey (Türkiye)
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

The Türkiye Heart Failure (TURK-HF) Registry

Overview

A comprehensive understanding of the socio-demographic, clinical, and biological characteristics of patients with heart failure is essential to develop novel strategies for improving outcomes. The identification of the barriers to guideline-directed medical therapy implementation in a real-world setting is critical to decreasing the risk of heart failure hospitalization and mortality. A comprehensive and well-designed heart failure registry can determine the clinical characteristics of patients with heart failure, identify patient, physician, and healthcare system-related factors for the non-use of evidence-based therapies, and improve the implementation of guideline-directed medical therapy. It should be noted that the number of heart failure registries that enroll patients with de novo heart failure, chronic heart failure (outpatients), and worsening of heart failure (hospitalized or treated in the emergency department), with all three relevant ejection fraction categories (heart failure with reduced ejection fraction, heart failure with mildly-reduced ejection fraction, and heart failure with preserved ejection fraction), is limited. Furthermore, only a few registries assess detailed aspects of guideline adherence, treatment decisions, and both in-hospital and long-term outcomes. Therefore, the Türkiye Heart Failure (TURK-HF) registry has been designed to address this gap in knowledge about the identification, management, and long-term prognosis of patients with heart failure in a real-world setting.

Interventions

  • Other Heart failure medication
    Treated with optimal guideline-directed medical therapy

Primary outcome measures

  • Heart failure hospitalization [Time frame: From enrollment to the end of follow-up period at 12 months]
  • Cardiovascular mortality [Time frame: From enrollment to the end of follow-up period at 12 months]
  • Composite of heart failure hospitalization and cardiovascular mortality [Time frame: From enrollment to the end of follow-up period at 12 months]
Secondary outcome measures (1)
  • All-cause mortality [Time frame: From enrollment to the end of follow-up period at 12 months]

Eligibility criteria

Inclusion Criteria: Presence of heart failure -

Exclusion Criteria: Age <18 years

\-

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Turkey (Türkiye) · 1 center
  • Baskent University — Ankara

Publications

  • Kocabas U, Ergin I, Yavuz V, Altin C, Kaplan M, Yilmaz Oztekin GM, Dogdus M, Murat S, Murat B, Kivrak T, Karabulut D, Kaya E, Ozdemir IH, Yildiz C, Salkin FO, Ozcalik E, Polatkan SG, Cakan F, Sen T, Karabulut U, Cakal S, Oflar E, Sinan UY, Yenercag M, Turk UO. Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED-HEART study. ESC Heart Fail. 2025 Feb;12(1): PMID 39340234
  • Kocabas U, Ergin I, Kivrak T, Yilmaz Oztekin GM, Tanik VO, Ozdemir I, Avci Demir F, Dogdus M, Sen T, Altinsoy M, Ustundag S, Urgun OD, Sinan UY, Uygur B, Yeni M, Ozcalik E. Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction. ESC Heart Fail. 2023 Dec;10(6):3677-3689. doi: 10.1002/ehf2.14559. Epub 2023 Oct 7. PMID 37804042
  • Kocabas U, Kivrak T, Yilmaz Oztekin GM, Tanik VO, Ozdemir IH, Kaya E, Yuce EI, Avci Demir F, Dogdus M, Altinsoy M, Ustundag S, Ozyurtlu F, Karagoz U, Karakus A, Urgun OD, Sinan UY, Mutlu I, Sen T, Astarcioglu MA, Kinik M, Tok OO, Uygur B, Yeni M, Alan B, Dalgic O, Sariturk C, Altay H, Pehlivanoglu S. Adherence to guideline-directed medical and device Therapy in outpAtients with heart failure with PMID 32628147
  • Kocabas U, Murat S, Kivrak T, Murat B, Altin C, Yildiz C, Polatkan SG, Oskay SA, Ulutas Z, Inan D, Gunay N, Karabulut D, Cakan F, Yavuz V, Ergin I, Turk UO, Tengiz I; TURK-HF Registry Investigators. Rationale and Design of the Turkiye Heart Failure (TURK-HF) Registry. Clin Cardiol. 2026 May;49(5):e70353. doi: 10.1002/clc.70353. PMID 42165426

Identifiers

NCT: NCT06707220 · KA23/429

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗